Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 864 of 6351
-
New drug combo aims to wipe out hidden ovarian cancer cells
Disease control Recruiting nowThis is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
Phase 1/2 • Sponsor: Imunon • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Nasal spray shows promise for depression that Won't quit
Symptom relief Recruiting nowAn open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant depression when administered as monotherapy or as adjunctive…
Phase 2 • Sponsor: Beckley Psytech Limited • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New drug duo aims to shrink tough head and neck tumors
Disease control OngoingPhase Ib: To observe the safety and tolerability of SI-B001+SI-B003 in combination and to identify RP2D in locally advanced or metastatic head and neck squamous cell carcinoma indications. Initial efficacy, pharmacokinetic characteristics and immunogenicity were evaluated. Phase …
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Liver-targeted chemo may boost survival in bile duct cancer
Disease control CompletedPrognosis for unresectable intrahepatic cholangiocarcinoma (ICC) remains poor. Treatment combination known as Gemox (systemic chemotherapy of gemcitabine and oxaliplatin), along with lenvatinib and toripalimab, has shown favor results for ICC patients. However, Hepatic Arterial I…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Promising combo tackles rare blood cancer in chinese patients
Disease control OngoingThis study will use a combination of Brentuximab vedotin with CHP to treat adult Chinese participants with CD30+ PTCL. The main aims of the study are to evaluate: * Side effect from the A+CHP * Check how much A+CHP stays in their blood over time. This will help Takeda to work o…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a simple exercise program rewire emotional control in depression?
Symptom relief CompletedDepression is associated with difficulties in emotion regulation. Adapted physical activity (APA) may help improve emotional regulation in people with depressive disorders. The REAPAD study evaluates the effects of an adapted physical activity program on emotion regulation in ad…
Sponsor: Centre Hospitalier Georges Mazurelle • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC
-
New stem cell therapy aims to free patients from lifelong blood transfusions
Disease control CompletedThis is an open label, multi-center study to evaluate the safety and Efficacy of ET-01 Transplantation in subjects with Transfusion Dependent β-Thalassaemia.
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New imaging technique may spare throat cancer patients from unnecessary radiation
Disease control Recruiting nowThis study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SP…
Phase 3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New cocktail aims to shrink advanced kidney tumors
Disease control OngoingTo learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for rare lung cancer mutations: targeted pill tested after surgery
Disease control OngoingThis is an open-label, multi-centre, single-arm study assessing the efficacy and safety of osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after receiving complete surgical resection with or without adjuvant chemotherapy.
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New Gene-Silencing drug aims to reverse liver scarring in MASH patients
Disease control Recruiting nowThis study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH). MASH is a form of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD).…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Peanut allergy vaccine? new peptide therapy aims to protect kids
Disease control OngoingThe overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
Phase 2 • Sponsor: Aravax Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can a single drug free PMR patients from steroids?
Disease control OngoingPolymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing treatment. A proof of concept study on Rituximab (RTX) vs pl…
Phase 3 • Sponsor: Sint Maartenskliniek • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Can a generic cream match the brand for psoriasis relief?
Disease control CompletedTo compare the safety and efficacy of Padagis' product to an FDA approved product for the treatment of plaque psoriasis
Phase 3 • Sponsor: Padagis LLC • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug cocktail could rival standard bladder cancer therapy in major trial
Disease control OngoingThe study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New antibody aims to block muscle wasting in rare disease
Disease control OngoingThe purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New valve replacement offers hope for heart leak patients who can't have standard surgery
Disease control Recruiting nowEvaluate the safety and efficacy of Medtronic Intrepid™ TMVR TF System in patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC who, by agreement of the local …
Sponsor: Medtronic Cardiovascular • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can early MS patients pause treatment? new trial seeks answers
Disease control OngoingThis study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusi…
Phase 4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Experimental antibody boosts chemo in ovarian cancer trial
Disease control OngoingA clinical study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newl…
Phase 2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug aims to outsmart resistant colorectal cancer
Disease control OngoingKEYNOTE-177 is currently the only randomized controlled phase III clinical trial evaluating the efficacy and safety of pembrolizumab versus standard chemotherapy combined with targeted first-line therapy for dMMR/MSI-H metastatic colorectal cancer. The study was conducted at 192 …
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC